ReviewWorld journal of cardiology2014
Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclines.
Review in World journal of cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Cardiotoxic Effects of Osimertinib Compared to Other EGFR Inhibitors: A Systematic Review and Meta-Analysis.Cardiovascular toxicology · 2026Pooled it
- Dehydroevodiamine Alleviates Doxorubicin-Induced Cardiomyocyte Injury by Regulating Neuregulin-1/ErbB Signaling.Cardiovascular therapeutics · 2024Article
- The H2Bub1-deposition complex is required for human and mouse cardiogenesis.Development (Cambridge, England) · 2023Article
- Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine.Current issues in molecular biology · 2023Review
- Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.Frontiers in cardiovascular medicine · 2022Review
- Targeting Oxidative Stress, NLRP3 Inflammasome, and Autophagy by Fraxetin to Combat Doxorubicin-Induced Cardiotoxicity.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Multiple lectin assays in detecting glycol-alteration status of serum NRG1 in papillary thyroid cancer.Translational cancer research · 2021Article
- Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease.Clinical science (London, England : 1979) · 2020Review
- Doxorubicin-Induced Cardiomyopathy in Children.Comprehensive Physiology · 2019Review
- Cleavage and Sub-Cellular Redistribution of Nuclear Pore Protein 98 by Coxsackievirus B3 Protease 2A Impairs Cardioprotection.Frontiers in cellular and infection microbiology · 2019Article
- Dysregulation of Neuregulin-1/ErbB signaling in the hippocampus of rats after administration of doxorubicin.Drug design, development and therapy · 2018Article
- Increased expression of neuregulin 1 in the urothelium of rat bladder with partial bladder outlet obstruction.BMC urology · 2017Article
- Article
- Sarco"MiR" friend or foe: a perspective on the mechanisms of doxorubicin-induced cardiomyopathy.Annals of translational medicine · 2016Article
- Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening.Advanced drug delivery reviews · 2016Review
- A specified therapeutic window for neuregulin-1 to regenerate neonatal heart muscle.Annals of translational medicine · 2015Article
- Insights into cardio-oncology: Polypharmacology of quinazoline-based α1-adrenoceptor antagonists.World journal of cardiology · 2015Review
- The roles of neuregulin-1 in cardiac development, homeostasis, and disease.Biomarker insights · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuregulin-1 (NRG1) signaling through the tyrosine kinase receptors erbB2 and erbB4 is required for cardiac morphogenesis, and it plays an essential role in maintaining the myocardial architecture during adulthood. The tyrosine kinase receptor erbB2 was first linked to the amplification and overexpression of erbb2 gene in a subtype of breast tumor cells, which is indicative of highly proliferative cells and likely a poor prognosis following conventional chemotherapy. The development of targeted therapies to block the survival of erbB2-positive cancer cells revealed that impaired NRG1 signaling through erbB2/erbB4 heterodimers combined with anthracycline chemotherapy may lead to dilated cardiomyopathy in a subpopulation of treated patients. The ventricular-specific deletion of either erbb2 or erbb4 manifested dilated cardiomyopathy, which is aggravated by the administration of doxorubicin. Based on the exacerbated toxicity displayed by the combined treatment, it is expected that the relevant pathways would be affected in a synergistic manner. This review examines the NRG1 activities that were monitored in different model systems, focusing on the emerging pathways and molecular targets, which may aid in understanding the acquired dilated cardiomyopathy that occurs under the conditions of NRG1-deficient signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.